参考文献/References:
[1]Schoenfeld SR,Kasturi S,Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE:a systematic review[J]. Semin Arthritis Rheum,2013,43(1):77-95.
[2]Dhakal BP,Kim CH,Al-Kindi SG,et al. Heart failure in systemic lupus erythematosus[J]. Trends Cardiovasc Med,2018,28(3):187-197.
[3]Chen SK,Barbhaiya M,Fischer MA,et al. Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients[J]. Semin Arthritis Rheum,2019,49(3):389-395.
[4]Benvenuti F,Gatto M,Larosa M,et al. Cardiovascular risk factors,burden of disease and preventive strategies in patients with systemic lupus erythematosus:a literature review[J]. Expert Opin Drug Saf,2015,14(9):1373-1385.
[5]Urowitz MB,Gladman D,Ibanez D,et al. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus[J]. Arthritis Care Res (Hoboken),2010,62(6):881-887.
[6]Arnson Y,Shoenfeld Y,Amital H. Effects of tobacco smoke on immunity,inflammation and autoimmunity[J]. J Autoimmun,2010,34(3):J258-J265.
[7]Dunlay SM,Weston SA,Jacobsen SJ,et al. Risk factors for heart failure:a population-based case-control study[J]. Am J Med,2009,122(11):1023-1028.
[8]Shoenfeld Y,Gerli R,Doria A,et al. Accelerated atherosclerosis in autoimmune rheumatic diseases[J]. Circulation,2005,112(21):3337-3347.
[9]Petri M,Roubenoff R,Dallal GE,et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus[J]. Lancet,1996,348(9035):1120-1124.
[10]Bassi N,Ghirardello A,Iaccarino L,et al. OxLDL/beta2GPI-anti-oxLDL/beta2GPI complex and atherosclerosis in SLE patients[J]. Autoimmun Rev,2007,7(1):52-58.
[11]Kim CH,Al-Kindi SG,Jandali B,et al. Incidence and risk of heart failure in systemic lupus erythematosus[J]. Heart,2017,103(3):227-233.
[12]Sasson Z,Rasooly Y,Chow CW,et al. Impairment of left ventricular diastolic function in systemic lupus erythematosus[J]. Am J Cardiol,1992,69(19):1629-1634.
[13]Wislowska M,Deren D,Kochmanski M,et al. Systolic and diastolic heart function in SLE patients[J]. Rheumatol Int,2009,29(12):1469-1476.
[14]Chung HT,Huang YL,Yeh KW,et al. Subclinical deterioration of left ventricular function in patients with juvenile-onset systemic lupus erythematosus[J]. Lupus,2015,24(3):263-272.
[15]Godoy MFD,Oliveira CMD,Fabri VA,et al. Long-term cardiac changes in patients with systemic lupus erythematosus[J]. BMC Res Notes,2013,6:171.
[16]Karp I,Abrahamowicz M,Fortin PR,et al. Recent corticosteroid use and recent disease activity:independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?[J]. Arthritis Rheum,2008,59(2):169-175.
[17]Tsukamoto H,Nagafuji K,Horiuchi T,et al. A phaseⅠ-Ⅱ trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease[J]. Ann Rheum Dis,2006,65(4):508-514.
[18]Nakamae H,Tsumura K,Hino M,et al. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide[J]. Lancet,2000,355(9206):805-806.
[19]Pego-Reigosa JM,Lu TY,Fontanillo MF,et al. Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy:a retrospective observational study[J]. Rheumatology (Oxford),2010,49(4):691-696.
[20]Onuora S. Systemic lupus erythematosus:Rituximab improves SLE disease activity[J]. Nat Rev Rheumatol,2018,14(2):62.
[21]Tieng AT,Peeva E. B-cell-directed therapies in systemic lupus erythematosus[J]. Semin Arthritis Rheum,2008,38(3):218-227.
[22]彭方琴,汪汉,蔡琳. 脑钠肽与结缔组织疾病[J]. 心血管病学进展,2017,38(3):343-346.
[23]周涛,王晓云,杨红英,等. 系统性红斑狼疮合并心力衰竭患者心肌肌钙蛋白Ⅰ水平的监测及临床意义[J]. 检验医学与临床,2009,6(7):488-489.
[24]Zhang L,Wang GC,Ma L,et al. Cardiac involvement in adult polymyositis or dermatomyositis:a systematic review[J]. Clin Cardiol,2012,35(11):686-691.
[25]张翠,汪汉,蔡琳. 结缔组织病与心力衰竭[J]. 心血管病学进展,2018,39(4):677-681.
[26]Mavrogeni S,Karabela G,Stavropoulos E,et al. Heart failure imaging patterns in systemic lupus erythematosus. Evaluation using cardiovascular magnetic resonance[J]. Int J Cardiol,2014,176(2):559-561.
[27]Bissell LA,Anderson M,Burgess M,et al. Consensus best practice pathway of the UK systemic sclerosis study group:management of cardiac disease in systemic sclerosis[J]. Rheumatology(Oxford),2017,56(6):912-921.
[28]Ashrafi R,Garg P,McKay E,et al. Aggressive cardiac involvement in systemic lupus erythematosus:a case report and a comprehensive literature review[J]. Cardiol Res Pract,2011,2011:578390.
[29]Nikpour M,Urowitz MB,Ibanez D,et al. Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus:a prospective proof-of-concept cohort study[J]. Arthritis Res Ther,2011,13(5):R156.
[30]Huizinga TW,Bax JJ,Boumpas DT,et al. Heart failure as presenting manifestation of cardiac involvement in systemic lupus erythematosus[J].Neth J Med,2009,67(9):295-301.
[31]Nawata T,Kubo M,Fujii S,et al. Treatment of class Ⅳ lupus nephritis with mycophenolate mofetil monotherapy[J]. Intern Med,2018,57(14):2067-2070.
[32]Yuri Gasparyan A,Ayvazyan L,Cocco G,et al. Adverse cardiovascular effects of antirheumatic drugs:implications for clinical practice and research[J]. Curr Pharm Des,2012,18(11):1543-1555.
[33]Hahn BH,McMahon MA,Wilkinson A,et al. American College of Rheumatology guidelines for screening,treatment,and management of lupus nephritis[J]. Arthritis Care Res (Hoboken),2012,64(6):797-808.
[34]Eriksson K,Svenungsson E,Karreskog H,et al. Physical activity in patients with systemic lupus erythematosus and matched controls[J]. Scand J Rheumatol,2012,41(4):290-297.
[35]Parker B,Al-Husain A,Pemberton P,et al. Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus[J]. Ann Rheum Dis,2014,73(6):1144-1150.
[36]Mavrogeni S,Koutsogeorgopoulou L,Dimitroulas T,et al. Complementary role of cardiovascular imaging and laboratory indices in early detection of cardiovascular disease in systemic lupus erythematosus[J]. Lupus,2017,26(3):227-236.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(3):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(3):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(3):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(3):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(3):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(3):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(3):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(3):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]